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Background: Several members of the common gamma chain (gc) cytokine family are already approved (IL-2)
or actively being developed as vaccine adjuvants and cancer immunotherapies. Studies have indicated that
co-administration of gc cytokines may enhance the efficacy of immunotherapies that function via direct activation
of co-stimulatory T cell receptors. To define the specific influence of gc cytokines on the co-stimulatory capacity
of CD8+ T cells and identify combinations with synergistic potential, we investigated the direct impact of gc
cytokines on the differentiation and transcriptional profile of recently antigen-primed CD8+ T cells.
Methods: Naïve CD8+ T cells were activated with peptide-pulsed APCs. After 48 hours, CD8+ T cells were harvested
and re-cultured in media supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21. After 24 hours, cells were analyzed by
cytokine bead array, flow cytometry, and mRNA micro-array. Gene networks responsible for specific CD8+ T cell
functions were constructed through literature-meta review and publicly available annotation databases. Gene
expression data from the experimental groups was imported into this network to visualize the impact of each gc
cytokine on the functional polarization of recently-activated CD8+ T cells.
Results: Among the gc cytokines, IL-2 induced the greatest increase in the expression of co-stimulatory receptors
in recently-activated CD8+ T cells. IL-2 increased significantly expression of 4-1BB, GITR, ICOS and OX40, at both
the transcriptional and protein level. IL-2 also drove the greatest increase in cellular proliferation and the most robust
shift towards a pro-survival phenotype, compared with the other gc cytokines. Both IL-4 and IL-21 enhanced expression
of cytotoxic effector proteins, but drove distinct phenotypic polarizations, Th2/Tc2 and NK-like, respectively.
Conclusions: Overall, these observations suggest that among gc cytokines, IL-2 may be uniquely capable of
synergizing with therapeutic strategies that combine immunization with agonists of co-stimulatory T cell receptors.
Previous studies have shown that the timing of IL-2 treatment relative to immunization plays a key role in defining the
CD8+ T cell response, and the findings from this study indicate that administration of exogenous IL-2 shortly after
the initial antigen-priming event has concluded may augment the receptivity of these cells to subsequent TNFR
co-stimulation.
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The common gamma chain (γc) receptor family of cyto-
kines has a central role in the regulation of both innate
and adaptive immunity. A subset of type I cytokines, the
γc family, includes interleukin-2 (IL-2), IL-4, IL-7, IL-9,
IL-15 and IL-21. Each of these cytokines signals via a mul-
timeric receptor complex that incorporates the common
gamma chain receptor, CD132. The γc cytokines are espe-
cially important in lymphocyte development, where they
influence polarization, proliferation and survival [1]. Be-
cause of this influence, the therapeutic potential of γc
family cytokines has been investigated in the context of
numerous biomedical applications, notably cancer im-
munotherapy [2,3]. High dose IL-2 therapy, which drives
an expansion of lymphocyte populations, is currently ap-
proved by the FDA for the treatment of metastatic melan-
oma and renal cancer [4]. The remaining γc cytokines,
with the exception of IL-9, are at various stages of pre-
clinical development for immunotherapy applications [1].
Beyond their utility as monotherapies, ongoing research
has indicated that the combination of exogenous γc cyto-
kines with agonistic monoclonal antibodies that target
TNFR family receptors on T cells can enhance anti-tumor
immunity in multiple cancer models [5,6]. Thus, a thor-
ough understanding of how γc cytokines modulate and
potentiate TNFR signaling in activated CD8+ T cells is im-
portant for the development of better combinatorial can-
cer immunotherapies.
Following TCR stimulation, CD8+ T cells undergo clonal
expansion, acquire effector functions and can be polarized
in multiple dimensions; cytokine production vs. cytolytic
activity, short-lived vs. long-lived, co-stimulatory vs. co-
repressive, peripheral vs. central homing, etc. [7,8]. From a
general perspective, CD8+ T cells can be polarized into
Tc1, Tc2, and Tc17 cell populations, which parallel the
polarization of CD4+ T cells into Th1, Th2, and Th17 cell
populations, respectively [9]. The γc cytokines appear to
be critical determinants of how CD8+ T cells progress
through these developmental pathways [10]. Their recep-
tor complexes utilize shared subunits that transduce over-
lapping signals via the JAK–STAT pathway and the
differential activation of STAT pathways likely contributes
to the distinct effects induced by each γc cytokine [11].
For leukocytes in general, IL-2, IL-7, and IL-15 have been
shown to preferentially activate STAT5, while IL-4 and IL-
21 preferentially activate STAT6 and STAT3, respectively .
For CD8+ T cells specifically, recent work has suggested
that IL-4 and IL-21 signal largely through STAT3, with
minimal activation of STAT6 [1]. As a result of these
unique signal transduction pathways, each γc cytokine
likely has a distinct impact on the development and func-
tion of recently activated CD8+ T cells, and by extension,
their capacity to respond to various signals via the TNFR
family of cell surface receptors.Ligation of co-stimulatory T cell receptors, such as
OX40 (Tnfrsf4, CD134), 4-1BB (Tnfrsf9, CD137) and
GITR (Tnfrsf18, CD357), with agonist mAbs has been
shown to augment the anti-tumor immune response in
numerous cancer models [12]. Exposure to IL-2 up-
regulates OX40 expression on effector CD8+ T cells and
IL-2 therapy has been shown to enhance the therapeutic
efficacy of an agonist anti-OX40 mAb [6]. The potential
synergy between γc cytokines and T cell stimulating mAbs
offers the prospect of significantly improved therapeutic
outcomes. However, the molecular mechanisms by which
γc cytokines influence the TNFR-dependent signaling net-
works of T cells remain largely unexplored. While the sys-
temic effects of administering exogenous γc cytokines have
been investigated in animals and humans, the complexity,
redundancy, and cross-talk within the γc signaling network
presents a challenge to defining the direct effects of
each γc cytokine on specific lymphocyte subpopulations.
The purpose of this study was to investigate the direct in-
fluence of γc family cytokines on the differentiation and
polarization of freshly antigen-primed CD8+ T cells in an
effort to better define the functional relationship between
γc cytokines and TNFR-mediated co-stimulation in this
population.
Results
The γc cytokines differentially impact the proliferation
and survival of recently activated CD8+ T cells
In this experimental model, activated CD8+ T cells are
purified shortly after antigen-priming and cultured in
the presence of individual γc cytokines to define their
direct effect on short term differentiation of this T cell
population. A significant increase in cellular prolifera-
tion, relative to untreated controls, was observed in re-
sponse to treatment with all of the γc cytokines except
IL-21 (Figure 1A), with IL-2 driving the most robust ex-
pansion. The proportion of viable cells was largely con-
sistent in each treatment group, and all of the treatment
groups had a significantly higher proportion of viable
cells than the untreated control (Figure 1B). The differ-
ences in proliferation were paralleled at the protein level
by the anti-apoptotic transcription factor, BCL2, which
was elevated in all of the treatment groups and observed
at greatest abundance in response to IL-2. In contrast,
several markers of T cell activation (Ki-67, CD69 and
KLRG1) were detected at levels that were consistent
across all experimental groups (Figure 1C-D).
IL-2 uniquely enhances the expression of several
co-stimulatory TNFR family receptors on activated CD8+
T cells
The ligation of co-stimulatory receptors on the surface of
effector CD8+ T cells is known to support their survival
and cytotoxic activity. Four of the most thoroughly
Figure 1 Influence of γc cytokines on proliferation, survival and activation state of recently-activated CD8+ T cells. Purified naïve OT-I
CD8+ T cells (1x106/ml) were stimulated with peptide-pulsed APCs (6x106/ml). After 48 hours, OT-I T cells were harvested, re-purified and re-cultured
(5x105/ml) in the presence of either plain media or media supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21 (100 ng/ml). After 24 hours, cells
were harvested and the analyzed. A) Expansion of OT-I CD8+ T cells in response to each treatment condition. B) Percentage of viable cells in
each condition, as determined by Trypan Blue exclusion. C, D) Flow cytometry analysis of T cell markers associated with activation state,
proliferation and exhaustion. Data are generated from 3 biological replicates, histograms reflect a single representative biological replicate and
the bar graphs depict the mean of replicates +/−SD (n = 3). Unless otherwise noted, significance reflects the difference between the treatment
group and the media only control. *P < 0.05, *P < 0.01, ***P < 0.001.
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(CD137), GITR (CD357), ICOS (CD278) and OX40
(CD134). While several of these receptors appeared
moderately up-regulated by multiple γc cytokines, IL-2
treatment induced a uniquely robust and statistically
significant increase in expression of each of these re-
ceptors at the protein level (Figure 2A-B). Each γc cyto-
kine also drove a distinct response with respect to co-
repressive and suppressive T cell receptors. IL-2 treat-
ment uniquely induced a significant increase in BTLA
(CD272) and an apparent, but not statistically signifi-
cant, increase in CTLA-4 (CD152), relative to thecontrol (Figure 3C-D). Meanwhile, PD-1 (CD279) was
significantly up-regulated in the IL-15 and IL-21 groups,
compared to the control, while expression of TIM-3
(HAVCR2), a negative regulator of Th1/Tc1 T cells, was
similar at the protein level across all treatment groups and
controls.
IL-4 and IL-21 induce a unique increase in transcription
factors and effector proteins associated with cytotoxic
functions
T-bet, a transcription factor associated with T cell ef-
fector function, was elevated in response to all of the
Figure 2 Effect of γc cytokines on the expression of co-stimulatory and co-repressive receptors by recently-activated CD8+ T cells.
Purified naïve OT-I CD8+ T cells (1x106/ml) were stimulated with peptide-pulsed APCs (6x106/ml). After 48 hours, OT-I T cells were harvested, re-purified
and re-cultured (5x105/ml) in the presence of either plain media or media supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21 (100 ng/ml). After 24 hours,
cells were harvested and the analyzed by intracellular cytokine staining and flow cytometry. A, B) Expression of co-stimulatory CD8+ T cell receptors.
C, D) Expression of co-repressive and suppressive CD8+ T cell receptors. Data are generated from 3 biological replicates, histograms reflect a single
representative biological replicate and the bar graphs depict the mean of replicates +/−SD (n = 3). Unless otherwise noted, significance reflects the
difference between the treatment group and the media only control. *P < 0.05, *P < 0.01, ***P < 0.001.
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tistically significant for IL-4 and IL-21. GATA-3 had a
similar expression profile as T-bet, although it was up-
regulated at substantially higher levels by IL-4, comparedto the other treatment groups. These two observations
were notable because T-bet and GATA-3 are known to be
essential for competing phenotypic polarizations, Tc1/Th1
and Tc2/Th2, respectively [13,14]. Eomes, a transcription
Figure 3 Impact of γc cytokines on the production of transcription factors and cytotoxic effector proteins in recently-activated CD8+ T
cells. Purified naïve OT-I CD8+ T cells (1x106/ml) were stimulated with peptide-pulsed APCs (6x106/ml). After 48 hours, OT-I T cells were harvested,
re-purified and re-cultured (5x105/ml) in the presence of either plain media or media supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21 (100 ng/ml).
After 24 hours, cells were harvested and the analyzed by intracellular cytokine staining and flow cytometry. A, B) Production of transcription factors
associated with T cell fate determination. C, D) Production of effector proteins associated with cytotoxic CD8+ T cell function. Data are generated from
3 biological replicates, histograms reflect a single representative biological replicate and the bar graphs depict the mean +/−SD (n = 3). Unless otherwise
noted, significance reflects the difference between the treatment group and the media only control. *P < 0.05, *P < 0.01, ***P < 0.001.
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regulation of central vs. effector CD8+ T cell differentiation
also appeared elevated by several γc cytokines, but these in-
creases did not reach statistical significance (Figure 3A-B).
The production of cytotoxic effector proteins was also
differentially influenced by treatment of CD8+ T cells
with exogenous γc cytokines (Figure 3C-D). Levels ofgranzyme B were significantly increased by each of the
cytokines except IL-15, with the highest levels induced
IL-21. Meanwhile, granzyme A production was driven
primarily by IL-4 and IL-21, with only the IL-21 group
reaching significance. Expression of perforin and FasL
(CD178) remained relatively consistent, at the protein
level, across treatment groups and controls.
Figure 4 (See legend on next page.)
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Figure 4 Differential changes in the functional polarization of CD8+ T cells induced by each γc cytokine. A-E) Genes are grouped into
functional clusters reflecting distinct biological processes associated with CD8+ T cells. Functional clusters each contain multiple genes, which are
represented as individual dots. Up-regulation (red) and down-regulation (blue) of gene expression are represented by color, and the amplitude of
the change is represented by the size of the point. Values represent the mean of three biological replicates. Lines connecting genes represent
putative gene-gene interactions, as defined by the Reactome FI database. Annotation of each cluster is based on a combination of a literature
meta-study and the GO annotation database. Complete gene cluster, transcriptomic data and probe information is included in Additional file 3:
Table S2. F) 3-dimensional bubble chart illustrating the distribution of all biological replicate from each experimental condition along three functional
axes: pro-survival vs pro-apoptotic, peripheral homing vs central homing, and Tc1/Th1 vs Tc2/Th2 polarization.
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recently antigen-primed CD8+ T cells reveals activation of
distinct molecular pathways
To better define the impact of γc cytokines on CD8+
T cell differentiation, and corroborate the preceding
flow cytometry-based observations, the transcriptomic
changes that occurred in each treatment group were
profiled by mRNA/cDNA microarray. The resulting data
set was filtered and sorted to highlight genes with known
relevance to T cell biology and grouped into functionally
and/or structurally related clusters (Figure 4, Additional
file 1: Table S1A). With respect to autocrine γc signaling,
the transcriptional data was consistent with observations
from the cytokine bead array that showed minimal en-
dogenous production of γc cytokines in any of the experi-
mental groups (Additional file 2: Figure S1). In the case of
IL-2, IL-4 and IL-21, exposure to those cytokines induced
transcriptional up-regulation of their corresponding re-
ceptors, potentially supporting a positive feedback loop
for signaling by these cytokines. However, at the protein
level, evidence of positive feedback was only observed for
the IL-2 receptor, CD25. Consistent with previous reports
about recently-activated CD8+ T cells, the transcriptomic
data indicated that the IL-9 receptor, CD129, was not sub-
stantially expressed in any of the conditions tested, and
that the IL-15 receptor, CD215, was expressed at a signifi-
cantly lower level than the other γc cytokine receptors. In
this study, IL-15 did not induce dramatic changes in any
of the assessed parameters, a finding which contrasts with
those of several other studies investigating the impact of
IL-15 on CD8+ T cells [15–19]. The low expression levels
of the IL-15 receptor in this particular CD8+ T cell popu-
lation may account for the muted effect of IL-15 treat-
ment, relative to the other γc cytokines.
A survey of genes associated with the regulation of cell
survival highlighted a clear shift towards a pro-survival
phenotype in all of the γc treatment groups, although
this shift was most robust in the IL-2 group. Notably,
the apoptosis facilitators Bim, Caspase-2 and Dapl1 were
notably down-regulated in the IL-2 treatment group,
while the apoptosis inhibitors BCL2, BCL-XL, and Bnip3
were up-regulated in each treatment group, with the
greatest increase observed in the IL-2 and IL-4 groups.The transcriptional profile of T cell co-stimulatory recep-
tors was largely consistent with the changes observed by
flow cytometry, with 4-1BB, OX40, GITR all up-regulated
by each γc cytokine and the most robust responses ob-
served in the IL-2 treatment group. In contrast to the
TNFR family co-stimulatory receptors, expression of the
co-repressive receptors BTLA-4 and CD160 trended down
in each treatment group, while expression of CTLA-4
remained stable. Expression of both PD-1 and TIM-3 were
uniquely elevated in the IL-21 treatment group.
Transcriptional profiling of the granzyme family of
cytotoxic effector proteins revealed distinct expression
profiles in each treatment group that may reflect a diver-
gence in the specificity and capacity of cytotoxic func-
tion. Expression of granzyme B, while highest in the IL-2
treatment group was up-regulated in response to all the
γc cytokines, while granzymes A and C were elevated
primarily in response to IL-4 and IL-21. Meanwhile the
up-regulation of granzyme D, granzyme K and perforin
was restricted to the IL-21 group. Parallel to these obser-
vations, the expression of two primary transcription fac-
tors that support T cell cytotoxic function, PRDM1
(Blimp1) and T-bet, closely mirrored changes observed
in granzyme expression. Interestingly, the expression
profile of PRDM1 largely matched that of granzyme B,
while the profile of T-bet matched that of granzymes A
and C. This correlation may be indicative of a direct
connection between the expression of these particular
transcription factors and cytotoxic effector genes.
The γc cytokines also induced distinct changes in the
expression of genes associated with intercellular adhe-
sion and chemotaxis. The most striking of these changes
was a dramatic down-regulation in all of the γc treat-
ment groups of the alpha-epsilon integrin (CD103), a
gene associated with both epithelial localization and sup-
pressive T cell populations. Several receptors associated
with central homing, including CD62L and CCR7 were
also generally down-regulated by γc treatment. With re-
spect to peripheral homing, a striking difference was ob-
served between the IL-21 group and the other γc cytokines,
with IL-21 inducing the substantial up-regulation of CCR2
and CCR5, both of which are chemokine receptors that
help lymphocytes migrate towards sites of inflammation.
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signaling and transcriptional regulation identified several
striking differences in how each treatment modulates
intracellular signal transduction. The suppressor of cyto-
kine signaling (SOCs) proteins are negative feedback reg-
ulators of JAK/STAT signaling and their transcriptional
regulation can be a useful indicator of pathway activation.
SOCS2 was dramatically up-regulated in response to IL-2
and IL-7, and to a lesser extent in the IL-4 group. Mean-
while, SOCS3 was substantially up-regulated in the IL-4
and IL-21 groups, with minimal changes in the others. IL-
2, IL-4 and IL-7 all induced moderate up-regulation of
SOCS1 and SOCS6, while little change was observed in
the expression SOCS4, SOCS5 and SOCS7.
Visualization of transcriptomic data in functionally-related
networks illustrates the distinct polarization profile
induced by each γc cytokine
To contrast the impact of each γc cytokine on the
polarization of distinct CD8+ T cell functions, we defined
clusters of genes that are directly associated with, or
supportive of, specific functions and phenotypes. These
gene clusters were assembled by integrating data from
publicly available databases with a T cell oriented litera-
ture review of genes associated with specific lympho-
cyte functions. The genes comprising the functional
clusters (long-lived/pro-survival, short-lived/pro-apop-
tosis, peripheral homing, central homing, cytotoxic effec-
tors, co-stimulatory receptors, co-repressive receptors,
NK-like markers, Th1/Tc1 markers, Th2/Tc2 markers and
markers of suppressive T cells) were overlaid with the
transcriptomic data generated in this study (Additional
file 3: Table S2). These gene clusters, their correspond-
ing expression data and annotated gene-gene interac-
tions were then visualized in an effort to illustrate how
each γc cytokine drives the polarization of recently-
activated CD8+ T cells in multiple functional dimen-
sions (Figure 4A-E). Polarization along three specific
axes (Tc1/Th1 vs Tc2/Th2, Long-lived vs Short-lived,
Peripheral homing vs Central homing) was also visualized
in 3 dimensions for each biological replicate, to illustrate
the functional clustering and consistency between samples
(Figure 4F).
This analysis indicates that all of the γc cytokines drive
expression of pro-survival genes and suppression of pro-
apoptotic genes, with IL-2 inducing the most robust re-
sponse. Overall, each of the γc cytokines suppress genes
associated with central homing and up-regulate those
associated with peripheral chemotaxis, although periph-
eral homing pathways are more dramatically induced by
IL-21, compared to the other cytokines. Similarly, all of
the cytokines drive expression of the cytotoxic effector
cluster, but IL-21 induces expression of more of these
genes, and at much higher levels. The polarizationbetween NK-like, Th1/Tc1, Th2/Tc2 and suppressive
clusters offers an intriguing perspective on the func-
tional impact of the respective γc cytokines. While the
features that delineate Th1/Tc1 and Th2/Tc2 popula-
tions are generally well-defined, the NK-like T cell popu-
lation remains somewhat amorphous [20]. NK-like T
cells are broadly defined as cytotoxic T cells that are
major histocompatibility complex-unrestricted, surface
CD3+, express NK-cell antigens, and rearrange their T-cell
receptor [21]. There are a variety of phenotypic and func-
tional subsets within this class, but this analysis is primar-
ily restricted to broadly conserved NK markers, such as
KLRC1 (NKG2A), KLRK1 (NKG2D), and KLRD1 (CD94).
IL-2, IL-7 and IL-15 up and down-regulate a mix of genes
in each cluster and do not appear to have a clear
polarization bias, although they each appear to down-
regulate the NK-like cluster. Meanwhile, IL-4 shows a
clear polarization towards the Th2/Tc2 cluster, at the ex-
pense of NK-like features. In contrast, IL-21 drives a ro-
bust up-regulation of both the NK-like and Th1/Tc1
cluster, while leaving the Th2/Tc2 cluster largely
unchanged.
Discussion
Although the systemic effects of administering exogen-
ous γc cytokines have been investigated in both in vitro
and in vivo systems, the complexity and interdependence
of the γc signaling network presents a challenge to de-
fining the direct effects of each γc cytokine on specific
lymphocyte subpopulations. The present study addresses
that challenge by characterizing the direct influence of
γc cytokines on the differentiation, survival, and co-
stimulatory potential of recently-activated Ag-specific
CD8+ T cells within an experimental system designed to
limit non-target cytokine signaling and cell-cell interac-
tions. Specifically, this study interrogated how each γc
cytokine altered the short-term differentiation of recently-
activated CD8+ T cells when administered in the absence
of additional stimuli and antigen-specific re-challenge.
Our observations indicate that while all of the γc cyto-
kines drive a set of shared outcomes in this population,
they each induce a unique profile of phenotypic and func-
tional polarization. Viewed in light of previous studies, the
findings from this study demonstrate the importance of
timing and context on the patterns of CD8+ T cell differ-
entiation induced by exposure to specific γc cytokines.
Administration of γc cytokines in vivo has been shown
to increase a variety of circulating lymphocyte populations,
including CD8+ T cells [18,22–27]. Consistent with those
findings, we observed that all of the γc cytokines tested,
with the exception of IL-21, supported a significant in-
crease in both cell survival and proliferation, compared to
untreated controls. Underlying these proliferative changes,
we observed that expression of the anti-apoptotic factor,
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protein and transcriptional levels, while several markers of
T cell activation and exhaustion, including Ki-67, CD69
and KLRG1 remained unchanged. The transcription of
several genes required for glucose metabolism and cell
growth, such as hexokinase 2 and fatty acid desaturase 2,
were also markedly up-regulated in response to all of
the cytokines tested. Functional grouping of transcrip-
tomic data into pro-survival and pro-apoptotic clusters
highlighted a clear shift towards a pro-survival tran-
scriptional program, particularly in groups treated with
IL-2 and IL-4, although this shift was muted in the IL-21
group. Furthermore, several receptors of pro-apoptotic
signals, such as FasR and PD-1 were down-regulated by
IL-2, IL-4 and IL-7, while treatment with IL-21 increased
expression of these markers. In total, these findings sug-
gest that the increase in CD8+ T cell populations ob-
served following administration of γc cytokines,
particularly IL-2, may reflect not just an enhancement
of metabolic and proliferative cellular activity, but also a
decreased sensitivity to anti-proliferative and pro-
apoptotic signals.
Previous studies have indicated that treatment with ex-
ogenous IL-21 enhances tumor infiltration and the cyto-
toxic function of effector CD8+ T cells in vivo [28–31].
In this study, we observed that IL-21 uniquely increased
expression of several chemokine receptors that are im-
portant for peripheral homing, notably CCR2, CCR5 and
CXCR6 [32,33]. Conversely, IL-2, IL-4 and IL-7 uniquely
elevated expression of CCR4, a chemokine receptor that
is also associated with peripheral homing. A similar split
was observed among chemokine ligands, with IL-21
uniquely inducing expression of the MIP family ligands
(CCL3, CCL4 and CCL9), which are associated with
acute inflammation and recruit a range of leukocytes
[34]. All of the treatment groups showed a decrease in
the expression of key genes associated with central hom-
ing (CCR7, CD62L) and homing to epithelial tissues
(Itgae/CD103, CCR9). The expression of genes associ-
ated with cytotoxic function, were increased by all of the
γc cytokines, although the magnitude of this increase
was greatest in response to IL-4 and IL-21. Taken to-
gether, these observations suggest that each of the γc cyto-
kines support the development of cytotoxic capabilities
and the migration of recently-activated T cells into the
periphery, although not necessarily to epithelial tissues.
However, IL-21 treated cells appear primed to follow a
distinct chemokine gradient mediated by CCR2 and
CCR5, one that is more likely to arise from sites of
acute inflammation in the periphery [35].
Perhaps the most striking results observed in this
study were the distinct differences in the polarization of
CD8+ T cells along the traditional Tc1/Th1 and Tc2/Th2
axes [8,10,36,37]. Tc1 and Tc2 are designations of CD8+T cell subsets that mirror those for Th1 and Th2 CD4+
T cells, respectively [38]. Tc1 polarized CD8+ T cells are
generally capable of secreting abundant IFN-γ in re-
sponse to TCR activation, whereas Tc2 cells generally se-
crete little IFN-γ but significant amounts of IL-4, IL-5,
and IL-10 in response to the same stimuli [9,38]. Tc1
and Tc2 cells are also reported to employ distinct com-
plements of chemokine receptors, with Tc1 cells express-
ing abundant CCR5, while Tc2 cells express abundant
CCR4 [39]. Both subsets have been shown to have prolifer-
ative and cytolytic capacities, although these attributes tend
to vary greatly between experimental models [40–43].
CD8+ T cells, at various stages of differentiation, have
been polarized into Tc1 and Tc2 subsets by treatment
with several different cytokine cocktails. For example,
CD8+ T cells can be polarized into Tc1 cells by a com-
bined treatment with IL-12, IFN-γ and an IL-4 neutraliz-
ing antibody. In contrast, these same cells can be driven to
a Tc2 phenotype by treatment with IL-4 and blockade of
IL-12 and IFN-γ [44]. Overall, we observed that IL-2 in-
duced a Tc1/Th1 phenotype, IL-4 induced a Tc2/Th2
phenotype, and IL-21 induced a combined Tc1/Th1 and
NK-like phenotype, while IL-7 and IL-15 did not have a
preferential impact on polarization. Consistent with nu-
merous previous reports, IL-4 treatment induced a sub-
stantial increase in GATA-3 expression, a transcription
factor associated with a Tc2/Th2 phenotype [45–48]. The
change in GATA-3 expression was accompanied by a
sharp increase in transcription among genes associated
with Tc2/Th2 functionality, notably CCR4 and IL-24.
Interestingly, IL-4 treatment also induced an increase
in T-bet expression, which is generally associated with
Tc1 polarized effector cells that produce IFN-γ following
TCR stimulation [49,50]. IFN-γ itself is also known to
induce T-bet expression in lymphocytes and myeloid
cells [51]. In context of the relatively promiscuous ex-
pression of T-bet across among lymphocyte subsets, the
observation here that both GATA-3 and T-bet are in-
creased in recently-activated CD8+ T cells may be evi-
dence that polarization between Th1/Tc1 and Th2/Tc2
is more dependent on the balance between T-bet and
GATA-3, than on the expression of the individual tran-
scription factors. An alternative possibility is that the ob-
servation regarding T-bet expression may simply be a
short-term event that does not persist through the devel-
opmental process.
In contrast, IL-21 induced a dramatic shift away from
a Tc2/Th2 orientation and towards a Tc1/Th1 pheno-
type, adopting a profile that has been described as “NK-
like”. CD8+ T cells with an NK-like phenotype display
several surface markers normally restricted to NK popu-
lations, including members of the KLRG and KLRK
killer cell lectin-like receptor families, and express sev-
eral distinct transcription factors [52–55]. NK-like CD8+
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expanded cytotoxic capabilities [56]. It is not entirely
clear precisely which features define this population and
what drives their formation, but it has been suggested
that high levels of IFN-γ can induce this phenotype, and
indeed expression of several markers of IFN-γ exposure,
such as the IFITM family of interferon-inducible trans-
membrane proteins (IFITM1, IFITM2, and IFITM3) were
substantially increased in the IL-21 treatment group [57].
However, expression of IFN-γ by the CD8+ T cells was
broadly, and relatively evenly, up-regulated across the
treatment groups, suggesting that the mechanism may in-
volve an altered sensitivity to IFN-γ or an alternative sig-
naling pathway, rather than a direct response to increased
concentrations of IFN-γ. Alternatively, several studies
have shown that CD8+ T cells can acquire NK-associated
markers and MHC-unrestricted cytolytic capabilities via
treatment with various cytokines, including IL-7, IL-12,
IL-15 and IL-21[15,55,56,58]. However, the inconsistent
phenotypic outcomes reported by these studies, as well as
the observations from this study, suggest that the capacity
of specific cytokines to induce an NK-like polarization in
CD8+ T cells may be largely defined by context and tim-
ing. While IL-4 and IL-21 drove divergent polarizations
along the Tc1/Th1 vs Tc2/Th2 axis in our model, the re-
sponse to IL-2, IL-4 and IL-15 was much more balanced.
IL-2 has been previously reported to support both Th1
and Th2 differentiation, at the expense of Th17 differenti-
ation [59]. However, IL-2 is also known to support the
overall expansion of lymphocyte populations, irrespective
of their functional orientation. In this model, we observed
that IL-2 did indeed primarily induce a balanced increase
in the expression of gene clusters associated with both
Th1/Tc1 and Th2/Tc2 polarizations. Underlying these
changes may be a positive feedback mechanism that aug-
ments the signal strength of specific γc cytokines. In this
model, we observed that treatment with IL-2, IL-4 and IL-
21 each significantly increased expression of their cognate
receptor, which may increase the sensitivity to each re-
spective cytokine (Figure 5, Additional file 2: Figure S1).
In an in vivo system that contains myriad competing sig-
nals, this feedback system may be important for facilitat-
ing a robust polarization in response to small changes in
cytokine concentration.
Numerous agonistic monoclonal antibodies that target
TNFR family receptors are undergoing pre-clinical and
clinical trials as immunotherapies for cancer [12,60].
Several studies have reported findings that suggest ad-
ministration of exogenous γc cytokines may augment
the efficacy of mAb therapies that target TNFR recep-
tors. Specifically, co-administration of IL-2 has been re-
ported to enhance the anti-tumor immune responses of
therapies targeting OX40 (CD134), GITR (CD357) and
4-1BB (CD137) [5,6,61,62]. In this study, we observedthat exposure to IL-2 led recently-activated CD8+ T cells
to substantially increase their expression of 4-1BB,
GITR, ICOS and OX40, at both the transcriptional and
protein level. The other γc cytokines also boosted the
transcriptional expression of these receptors to a lesser
extent, but at the protein level these increases only
reached statistical significance in one case, IL-7 induced ex-
pression of ICOS. Therefore, in this model it appears that
IL-2 is far more likely to enhance the capacity of recently-
activated CD8+ T cells to respond to co-stimulatory signals,
compared with other members of the γc family.
The observations reported in this study demonstrate
the importance of timing for the response of activated
CD8+ T cells to γc cytokines. A previous study by
Hinrichs, et al. reported that when exogenous IL-21 was
added to the culture media during antigen priming, the
acquisition of effector functions and the induction of
granzyme B were inhibited, while exogenous IL-2 and
IL-15 had an opposite effect, although this was not
maintained following adoptive transfer [63]. However, in
this study we observed that IL-21 treatment produced
the most robust induction of cytolytic effector function,
and several other studies have reported that exogenous
IL-21 enhances cytotoxic capacity of CD8+ T cells
in vivo. The key difference appears to be in both the tim-
ing and context of the stimuli. With respect to context,
the addition of exogenous γc cytokine during in vitro
antigen priming with a mixed population of leukocytes
will skew the balance of γc signaling in the system, but
the original complement of cytokines is still present. In
contrast, this model interrogates the response of CD8+
T cells that are isolated prior to stimulation, creating a
cytokine environment that is dominated by a single γc
cytokine. Although artificial, this type of isolated stimuli
may reflect some aspects of the environment encoun-
tered by the freshly-activated T cells as they migrate into
the periphery, where there may be fewer sources of γc
cytokine production in close proximity. Additionally, dif-
ferences in the timing of the γc stimuli clearly make a
critical difference. A short-term burst of IL-2 production
has been shown to accompany antigen-specific priming
of T cells, and unusually high levels of other γc cytokines
may disrupt the initial phases of rapid differentiation
that occur during early activation [64–66]. These obser-
vations raise the possibility that, as modulators of CD8+
T cell-mediated immunity, γc cytokines may be more
useful when administered after immunization, rather
than as a simultaneous treatment. Furthermore, the
rapid and dramatic up-regulation of multiple TNFR
family co-stimulatory receptors in response to IL-2 treat-
ment suggests that this γc cytokine may be uniquely well-
suited for co-administration with agonistic antibodies
targeting these receptors, particularly 4-1BB, GITR, ICOS
and OX40. Our findings also suggest that the cytotoxic
Figure 5 Transcription heat maps for selected gene families associated with CD8+ T cell differentiation and functionality. Purified naïve
OT-I CD8+ T cells (1x106/ml) were stimulated with peptide-pulsed APCs (6x106/ml). After 48 hours, OT-I T cells were harvested, re-purified and
re-cultured (5x105/ml) in the presence of either plain media or media supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21 (100 ng/ml). After 24 hours,
cells were harvested, mRNA isolated and gene expression analyzed by microarray. Data are generated from 3 biological replicates. Complete gene
and probe information is included in Additional file 1: Table S1.
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IL-21 treatment, and indeed it has been reported that a
combination of IL-21 with low dose IL-2 improves out-
comes in a murine melanoma model, in part by enhancing
the anti-tumor activity of CD8+ T cells [29].
Conclusions
Overall, this study suggests that among γc cytokines, IL-2
may be uniquely beneficial for therapeutic strategies that
combine immunization with agonists of co-stimulatory T
cell receptors. The data from this report, along with previ-
ous studies of γc cytokines and CD8+ T cell differentiation,
indicate that the timing of IL-2 administration relative to
immunization may play a critical role in defining the
resulting CD8+ T cell response [67]. In this study, we
found that administration of IL-2 significantly increased
the proliferation, survival and the expression of co-
stimulatory by CD8+ T cells when treatment followed
antigen-priming by 48 hours. In line with previous re-
ports, this study also found that IL-4 and IL-21 both in-
duced a robust acquisition of cytotoxic functions in this
population, albeit with dramatically different polarization
profiles, Th2/Tc2 and NK-like, respectively [68]. Those ob-
servations support the hypothesis that IL-21 may be useful
for promoting the cytotoxic function of peripheral CD8+
T cells, but because exogenous γc cytokine treatment may
disrupt antigen-priming, only after a population of acti-
vated, tumor-reactive CD8+ T cells is well-established.
Methods
Mice
Wild-type C57BL/6 mice were purchased from Jackson
Labs (Bar Harbor, ME). OT-I Thy1.1 TCR Tg mice were
bred in our facility. All mice were maintained under spe-
cific pathogen-free conditions in the Providence Portland
Medical Center animal facility. Experimental procedures
were performed according to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Cell isolation and preparation
Spleens were harvested from both wild-type C57BL/6
and OT-I Thy1.1 TCR Tg mice and processed to obtain
single cell suspensions. ACK lysing buffer (Lonza,
Walkersville, MD) was added for 5 min at RT to lyse red
blood cells. Cells were washed and re-suspended in
complete RPMI 1640 (Lonza) cell culture media supple-
mented with 10% FBS (Lonza), HEPES, non-essential
amino acids, sodium pyruvate (all from Lonza), and pen-
strep glutamine (Invitrogen). Whole splenocytes from
wild-type C57BL/6 mice were used as stimulator cells
and CD8+ T cells purified from OT-I splenocytes using
the Dynal mouse CD8+ T cell negative isolation kit (Invi-
trogen) were used as antigen-specific effector cells. Puri-
fied naïve wild-type OT-I (1 × 106/well) were stimulatedwith OVA peptide (SIINFEKL) pulsed (5 μg/ml) and ir-
radiated (2,000 rads) syngeneic splenocytes (6 × 106/well)
in 24-well plates. Forty-eight hours later, activated OT-I
T cells were harvested and viable cells were enriched
over a Ficoll-paque gradient and washed prior to being
re-seeded in media (5 × 105 cells/ml) and treated with
the γc cytokines. Recombinant murine IL-2, IL-4, IL-7,
IL-15 and IL-21 were purchased from eBioscience (San
Diego, CA). Experimental samples were treated with
100 ng/ml of their respective gamma chain cytokine and
incubated at 37°C for 24 hours.Cell proliferation and survival assays
The total number of viable cells post-treatment was
measured by counting, using trypan blue staining to ex-
clude dead cells. The viable proportion of CD8+/Thy1.1+
cells in each treatment group was quantified by flow cy-
tometry, using the eFluor780 viability dye (eBioscience).
The cell proliferation assay was conducted with three
biological replicates.Flow cytometry
The cells were pre-treated with a blocking mixture of anti-
CD16/32 and a mixture of polyclonal mouse and rat IgG
for 10 min at 4°C, then stained for 30 min at 4°C with the
following cytokines: CD8 BV785, Viability Dye eFluor780,
Thy1.1 eFluor450, Dump (CD11b, CD11c, CD19) AF70,
Granzyme-A APC, Granzyme-B PE, Perforin FITC, Gata-
3 eFluor710, T-bet PE-Cy7, BCL2 PE, Ki-67 FITC, Eomes
eFluor710, BTLA APC, OX40 PE, 4-1BB eFluor710, GITR
PE-Cy7, ICOS PerCP5.5, KLRG1 APC, TIM-3 PE, CTLA-
4 FITC, PD-1 PE-Cy7, CD215 APC, CD124 PE, CD127
APC, CD25 FITC, FasL eFluor710, and CD69 PE-Cy7.
All antibodies were obtained from eBioscience (San
Diego, CA), BD Biosciences (San Jose, CA), BioLegend
(San Diego, CA), Miltenyi Biotec (Bergisch Gladbach,
Germany), or Invitrogen. For intracellular staining, cells
were fixed and permeabilized with the Foxp3 Staining
Buffer Set (eBioscience) according to the manufactur-
er's instructions. Flow cytometry data was acquired on
a LSRII flow cytometer using FACSDiva software (BD
Biosciences). Data was processed and visualized with
FlowJo (Treestar, Ashland, Oregon). OneComp beads
(eBioscience) were used to define compensation settings.
Analyses were gated on viable/Thy1.1+/CD8+/Dump−
cells. Histograms were normalized to the mode and ob-
tained from representative samples. Mean fluorescent in-
tensities (MFI) was calculated using the mean MFI for
each target data sets representing three biological repli-
cates. Data sets were collated and imaged with Prism
(GraphPad Software, San Diego, CA), and statistical sig-
nificance was determined by one-way ANOVA.
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RNA was isolated using either the RNeasy Mini kit
(Qiagen, Valencia, CA) or a combination of TRIzol re-
agent (Life Technologies, Grand Island, NY, Grand Is-
land, NY) and the Direct-zol RNA miniprep kit (Zymo
Research, Irvine, CA), all following manufacturer proto-
cols. Two biological replicates for mRNA analysis were
prepped using the RNeasy kit. The third replicate was
prepped using the Trizol/Direct-zol approach. Prior to
submission to the Oregon Health & Science University
Gene Microarray Shared Resource core facility (Portland,
Oregon), the purity and quantity of the RNA was assessed
by NanoDrop ND-1000 (Thermo Scientific, Wilmington,
DE). The quality and quantity of RNA samples was further
analyzed on the Bioanalyzer platform (Agilent, Santa
Clara, CA). Labeled target cDNA was prepared from total
RNA samples using the Ambion MessageAmp Premier
protocol (3’IVT assay). Each sample target was hybridized
to a Mouse 430 2.0 GeneChip array (Affymetrix, Santa
Clara, CA). Image processing and expression analysis were
performed using Affymetrix GeneChip Command Con-
sole (AGCC) v. 3.1.1 and Affymetrix Expression Console
v.1.1 software, respectively. Data from all biological repli-
cates and conditions was imported into the Affymetrix Ex-
pression Console and normalized (RMA), annotated and
exported to CSV files, which were then processed in Excel.
Raw expression data is represented on a log2 scale and
data from biological replicates was averaged when com-
paring differences between experimental conditions.
Gene expression data processing and analysis
A log2 scale was used when representing raw gene ex-
pression values, and the relative changes between experi-
mental conditions. Averages of the biologic replicates for
each condition were used when comparing changes in
gene expression. The raw data for each replicate, treat-
ment averages, comparative changes, gene information
and probe ID for the genes included in Figure 5 are in-
cluded in Additional file 1: Table S1A. The complete
CEL files were deposited in the GEO database (accession
#GSE58262). Construction of functionally related gene
clusters utilized data from the GO annotation database,
as well as an aggregation of markers that have been re-
ported in the literature to be associated with specific T
cell functions and phenotypes. The list of genes in each
cluster, along with their expression and probe data, is
available in Additional file 3: Table S2. To visualize the
transcriptional changes in each functional cluster, the
gene clusters were imported into Cytoscape and each
cluster was represented as a circle of spots, each repre-
senting a specific gene in the cluster. Previously annotated
functional interactions between genes were identified and
illustrated with the Reactome FI plugin. Changes in gene
expression between each experimental group and theuntreated control were overlaid into the network and
visualized by amplitude (spot size) and direction (color;
up-regulated = red, down-regulated = blue).
Cytokine bead array
Supernatants from each treatment group and controls
were harvested and the concentration of cytokines was
measured by cytokine bead array via flow cytometry, fol-
lowing manufacturer protocols (eBioscience).
Additional files
Additional file 1: Table S1. Complete gene set and probe information.
Additional file 2: Figure S1. Autocrine γc cytokine signaling by recently
activated CD8 T cells treated with exogenous γc cytokines. Purified naïve
OT-I CD8+ T cells (1x106/ml) were stimulated with peptide-pulsed APCs
(6x106/ml). After 48 hours, OT-I T cells were harvested, re-purified and
re-cultured (5x105/ml) in the presence of either plain media or media
supplemented with IL-2, IL-4, IL-7, IL-15 or IL-21 (100 ng/ml). After 24 hours,
cells and supernatants were harvested and the analyzed. A) Secretion of
cytokines into the culture supernatant. B, C) Flow cytometry analysis of the
expression of specific γc receptors. Data are generated from 3 biological
replicates, histograms reflect a single representative biological replicate and
the bar graphs depict the mean of replicates +/−SD (n = 3). Unless otherwise
noted, significance reflects the difference between the treatment group and
the media only control. *P < 0.05, *P < 0.01, ***P < 0.001.
Additional file 3: Table S2. Complete gene cluster, transcriptomic data,
and probe information.
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